2006
Preliminary Evidence of Riluzole Efficacy in Antidepressant-Treated Patients with Residual Depressive Symptoms
Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, Krystal JH. Preliminary Evidence of Riluzole Efficacy in Antidepressant-Treated Patients with Residual Depressive Symptoms. Biological Psychiatry 2006, 61: 822-825. PMID: 17141740, PMCID: PMC2754299, DOI: 10.1016/j.biopsych.2006.08.037.Peer-Reviewed Original ResearchConceptsHamilton Depression Rating ScaleHamilton Anxiety Rating ScaleTreatment-resistant depressionMajor depressive disorderHARS scoresRating ScaleExcessive glutamatergic neurotransmissionEffects of riluzoleDepression Rating ScaleResidual depressive symptomsAnxiety Rating ScaleRiluzole efficacyMedication regimenAugmentation therapyContinuation phaseAntidepressant activityGlutamate neurotransmissionGlutamatergic neurotransmissionDepressive disorderAnxiolytic effectsDepressive symptomsRiluzolePatientsFirst weekLinear mixed models
1991
Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder
Woods S, Charney D, Silver J, Krystal J, Heninger G. Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. Psychiatry Research 1991, 36: 115-127. PMID: 1850142, DOI: 10.1016/0165-1781(91)90124-8.Peer-Reviewed Original ResearchConceptsAntagonist flumazenilAnxiolytic effectsBenzodiazepine receptor antagonist flumazenilReceptor antagonist flumazenilDose of flumazenilVisual analog scaleBenzodiazepine receptor functionBZR inverse agonistsSignificant anxiolytic effectSeparate test daysPlacebo capsulesBlood pressureAnalog scaleCardiovascular responsesDisorder patientsHeart rateFlumazenilCrossover designPanic patientsPanic disorderPlasma cortisolBaseline levelsPanic attacksPlaceboReceptor function